Brian Rini, MD

The panel explores unmet needs in aRCC treatment and shares expectations for changes and advances in the landscape in the near future.

Ongoing studies assessing triplet regimens in frontline advanced RCC and their influence on treatment decisions are discussed, including efficacy outcomes.

Panelists provide insight on ongoing studies evaluating doublet combinations in frontline advanced RCC.

Expert oncologists share experiences and insights on key treatment protocols for patients with aRCC, including perspectives from community oncologists.

The panel engages in a discussion on lenvatinib dosing in clinical practice, addressing dose reductions, their impact on treatment effectiveness, and real-world tolerability.

Panelists analyze the 4-year follow-up results of the CLEAR study, covering study design, efficacy, safety, and clinical implications.

Discussion centered around available first-line combination options for patients with aRCC as well as factors influencing treatment choice.

An overview of advanced Renal Cell Carcinoma (aRCC), including its prevalence, patient presentation, classification, and treatment criteria.

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses subgroup findings from the IMmotion151 trial in metastatic renal cell carcinoma. 

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses the basis for the ongoing phase III KEYNOTE-426 trial, which is exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) versus sunitinib (Sutent) alone in treatment-naive advanced metastatic renal cell carcinoma.

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).